These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 12943941

  • 1. Growth hormone and prolactin response to apomorphine in bipolar and unipolar depression.
    McPherson H, Walsh A, Silverstone T.
    J Affect Disord; 2003 Sep; 76(1-3):121-5. PubMed ID: 12943941
    [Abstract] [Full Text] [Related]

  • 2. Differences in multihormonal responses to the dopamine agonist apomorphine between unipolar and bipolar depressed patients.
    Monreal JA, Duval F, Mokrani MC, Fattah S, Palao D.
    J Psychiatr Res; 2019 May; 112():18-22. PubMed ID: 30836201
    [Abstract] [Full Text] [Related]

  • 3. Dopamine function in obsessive-compulsive disorder: growth hormone response to apomorphine stimulation.
    Brambilla F, Bellodi L, Perna G, Arancio C, Bertani A.
    Biol Psychiatry; 1997 Nov 15; 42(10):889-97. PubMed ID: 9359974
    [Abstract] [Full Text] [Related]

  • 4. Prolactin and growth hormone response to levodopa in affective illness.
    Linkowski P, Brauman H, Mendlewicz J.
    Neuropsychobiology; 1983 Nov 15; 9(2-3):108-12. PubMed ID: 6621850
    [Abstract] [Full Text] [Related]

  • 5. Multihormonal responses to apomorphine in mental illness.
    Mokrani MC, Duval F, Crocq MA, Bailey PE, Macher JP.
    Psychoneuroendocrinology; 1995 Nov 15; 20(4):365-75. PubMed ID: 8532820
    [Abstract] [Full Text] [Related]

  • 6. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
    Meltzer HY, Lee MA, Jayathilake K.
    Neuropsychopharmacology; 2001 Mar 15; 24(3):278-90. PubMed ID: 11166518
    [Abstract] [Full Text] [Related]

  • 7. Induction of tolerance of dopaminergic responses in man.
    Lal S, Thavundayil JX, Ng Ying Kin NM, Dai X, Schwartz G, Montoya A.
    J Neural Transm (Vienna); 2008 Aug 15; 115(8):1189-98. PubMed ID: 18506387
    [Abstract] [Full Text] [Related]

  • 8. Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats.
    Mueller GP, Simpkins J, Meites J, Moore KE.
    Neuroendocrinology; 1976 Aug 15; 20(2):121-35. PubMed ID: 958594
    [Abstract] [Full Text] [Related]

  • 9. Dopaminergic function and the cortisol response to dexamethasone in psychotic depression.
    Duval F, Mokrani MC, Crocq MA, Bailey PE, Diep TS, Correa H, Macher JP.
    Prog Neuropsychopharmacol Biol Psychiatry; 2000 Feb 15; 24(2):207-25. PubMed ID: 10800744
    [Abstract] [Full Text] [Related]

  • 10. Effect of some peptides on dopaminergic function in man.
    Lal S, Nair NP, Isaac I, Thavundayil J, Guyda H.
    J Neural Transm Suppl; 1990 Feb 15; 29():173-81. PubMed ID: 2113567
    [Abstract] [Full Text] [Related]

  • 11. Effects of short-term administration of valproate on serotonin-1A and dopamine receptor function in healthy human subjects.
    Delva NJ, Brooks DL, Franklin M, al-Said K, Hawken ER, Merali Z, Lawson JS, Ravindran AV.
    J Psychiatry Neurosci; 2002 Nov 15; 27(6):429-37. PubMed ID: 12491576
    [Abstract] [Full Text] [Related]

  • 12. Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms.
    Meltzer HY, Kolakowska T, Fang VS, Fogg L, Robertson A, Lewine R, Strahilevitz M, Busch D.
    Arch Gen Psychiatry; 1984 May 15; 41(5):512-9. PubMed ID: 6721674
    [Abstract] [Full Text] [Related]

  • 13. Apomorphine induced alteration in corneofundal potentials in depression.
    Demet EM, Albers L, Sokolski KN, Chicz-Demet A, Chen CC, Reist C.
    Prog Neuropsychopharmacol Biol Psychiatry; 1997 Jul 15; 21(5):775-88. PubMed ID: 9278949
    [Abstract] [Full Text] [Related]

  • 14. Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine and d-fenfluramine tests.
    Duval F, Mokrani MC, Monreal J, Bailey P, Valdebenito M, Crocq MA, Macher JP.
    Psychoneuroendocrinology; 2003 Jul 15; 28(5):627-42. PubMed ID: 12727131
    [Abstract] [Full Text] [Related]

  • 15. Stereospecificity of the dopamine receptor mediating the growth hormone response to apomorphine in man. Short communication.
    Lal S, Nair NP, Thavundayil JX, Tawar V, Quirion R, Guyda H.
    J Neural Transm Gen Sect; 1991 Jul 15; 85(2):157-64. PubMed ID: 1930878
    [Abstract] [Full Text] [Related]

  • 16. A study of dopaminergic sensitivity in Parkinson's disease: comparison in "de novo" and levodopa-treated patients.
    Llau ME, Durrieu G, Tran MA, Senard JM, Rascol O, Montastruc JL.
    Clin Neuropharmacol; 1996 Oct 15; 19(5):420-7. PubMed ID: 8889285
    [Abstract] [Full Text] [Related]

  • 17. Neuroendocrine responses to apomorphine in depressed patients and healthy control subjects.
    Jimerson DC, Cutler NR, Post RM, Rey A, Gold PW, Brown GM, Bunney WE.
    Psychiatry Res; 1984 Sep 15; 13(1):1-12. PubMed ID: 6595680
    [Abstract] [Full Text] [Related]

  • 18. Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan.
    Budde H, Zimmermann US, Steffin B, Rommelspacher H, Schmidt LG, Smolka MN.
    Alcohol Clin Exp Res; 2007 Jan 15; 31(1):100-3. PubMed ID: 17207107
    [Abstract] [Full Text] [Related]

  • 19. Effects of (+/-) 3,4-methylene-dioxymethamphetamine (ecstasy) on dopamine system function in humans.
    Gerra G, Zaimovic A, Moi G, Giusti F, Gardini S, Delsignore R, Laviola G, Macchia T, Brambilla F.
    Behav Brain Res; 2002 Aug 21; 134(1-2):403-10. PubMed ID: 12191827
    [Abstract] [Full Text] [Related]

  • 20. TRH tests with analyses of TSH, prolactin, and GH responses in subtypes of patients with major depressive disorders.
    Agren H, Wide L.
    Acta Psychiatr Scand; 1986 May 21; 73(5):549-58. PubMed ID: 3092581
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.